<?xml version="1.0" encoding="UTF-8"?>
<p id="Par65">1. Mild to Moderate COVID-19 associated with HIV/TB co-infection: Hospitalized in a special unit named COVID-19/TB units as risk patients. Start COVID-19 antiviral drugs, start or continue anti TB drugs according to the national guidelines and continue ART. Preferred COVID-19 antivirals are oseltamivir, chloroquine or hydroxychloroquine associated to LV/r or darunavir/cobicistat and Azithromycin may be indicated [
 <xref ref-type="bibr" rid="CR68">68</xref>]. Chloroquine: 1 g PO once on Day 1, then 500 mg PO once daily for 4–7 days, hydroxychloroquine: 800 mg PO once on Day 1, then 400 mg PO once daily for 4–7 days [
 <xref ref-type="bibr" rid="CR64">64</xref>] or lopinavir 400 mg/ritonavir 100 mg PO twice [
 <xref ref-type="bibr" rid="CR65">65</xref>]. All of them should be associated with Azithromycin [
 <xref ref-type="bibr" rid="CR64">64</xref>]. Drugs interactions should be reviewed as described above. Initial evaluation includes a chest x-ray, complete blood count (CBC), liver transaminases, renal function, inflammatory markers such as C-reactive protein (CRP), D-dimer, and ferritin, while not part of standard care, may have prognostic value.
</p>
